Regorafenib in Subjects With Antiangiogenic-naive and Chemotherapy-refractory Advanced Colorectal Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

59

Participants

Timeline

Start Date

July 21, 2015

Primary Completion Date

May 2, 2017

Study Completion Date

December 11, 2017

Conditions
Colorectal Neoplasms
Interventions
DRUG

Regorafenib (Stivarga, BAY73-4506)

Regorafenib 160 mg orally once a day for 3 weeks of every 4 week cycle (i.e., 3 weeks on, 1 week off).

Trial Locations (1)

01246000

São Paulo

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Bayer

INDUSTRY